dc.contributor.author | Adizie, JB | |
dc.contributor.author | Tweedie, J | |
dc.contributor.author | Khakwani, A | |
dc.contributor.author | Peach, E | |
dc.contributor.author | Hubbard, R | |
dc.contributor.author | Wood, N | |
dc.contributor.author | Gosney, JR | |
dc.contributor.author | Harden, SV | |
dc.contributor.author | Beckett, P | |
dc.contributor.author | Popat, S | |
dc.contributor.author | Navani, N | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2022-09-02T08:11:08Z | |
dc.date.available | 2022-09-02T08:11:08Z | |
dc.date.issued | 2021-06-01 | |
dc.identifier | 100176 | |
dc.identifier | S2666-3643(21)00035-7 | |
dc.identifier.citation | JTO Clinical and Research Reports, 2021, 2 (6), pp. 100176 - | |
dc.identifier.issn | 2666-3643 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5370 | |
dc.identifier.eissn | 2666-3643 | |
dc.identifier.eissn | 2666-3643 | |
dc.identifier.doi | 10.1016/j.jtocrr.2021.100176 | |
dc.description.abstract | INTRODUCTION: Optimal management of people with advanced NSCLC depends on accurate identification of predictive markers. Yet, real-world data in this setting are limited. We describe the impact, timeliness, and outcomes of molecular testing for patients with advanced NSCLC and good performance status in England. METHODS: In collaboration with Public Health England, patients with stages IIIB to IV NSCLC, with an Eastern Cooperative Oncology Group performance status of 0 to 2, in England, between June 2017 and December 2017, were identified. All English hospitals were invited to record information. RESULTS: A total of 60 of 142 invited hospitals in England participated in this study and submitted data on 1157 patients. During the study period, 83% of patients with advanced adenocarcinoma underwent molecular testing for three recommended predictive biomarkers (EGFR, ALK, and programmed death-ligand 1). A total of 80% of patients with nonsquamous carcinomas on whom biomarker testing was performed had adequate tissue for analysis on initial sampling. First-line treatment with a tyrosine kinase inhibitor was received by 71% of patients with adenocarcinoma and a sensitizing EGFR mutation and by 59% of those with an ALK translocation. Of patients with no driver mutation and a programmed death-ligand 1 expression of greater than or equal to 50%, 47% received immunotherapy. CONCLUSIONS: We present a comprehensive data set for molecular testing in England. Although molecular testing is well established in England, timeliness and uptake of targeted therapies should be improved. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 100176 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER | |
dc.relation.ispartof | JTO Clinical and Research Reports | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Biomarkers | |
dc.subject | Mutation testing | |
dc.subject | Non–small cell lung cancer | |
dc.subject | Personalized medicine | |
dc.subject | Targeted therapy | |
dc.title | Biomarker Testing for People With Advanced Lung Cancer in England. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-04-06 | |
dc.date.updated | 2022-09-02T08:10:47Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.jtocrr.2021.100176 | |
rioxxterms.licenseref.startdate | 2021-06-01 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/34590024 | |
pubs.issue | 6 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.jtocrr.2021.100176 | |
pubs.volume | 2 | |
dc.contributor.icrauthor | Popat, Sanjay | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-02. Deposit type is initial. No. of files: 1. Files: Biomarker Testing for People With Advanced Lung Cancer in England.pdf | |